Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-29
2010-06-15
Blanchard, David J (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07737138
ABSTRACT:
This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diaminophenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.
REFERENCES:
patent: 2928767 (1960-03-01), Gulesich et al.
patent: 5827644 (1998-10-01), Floyd et al.
patent: 6953794 (2005-10-01), Wischik et al.
patent: 2002/0168687 (2002-11-01), Wischik et al.
patent: 2006/0014216 (2006-01-01), Wischik et al.
patent: 2007/0116757 (2007-05-01), Rariy et al.
patent: 2007/0191352 (2007-08-01), Wischik et al.
patent: 2198256 (1995-08-01), None
patent: DE 1886 (1877-12-01), None
patent: 0 457 295 (1991-11-01), None
patent: 0 737 671 (1996-10-01), None
patent: 0 909 814 (1999-04-01), None
patent: 0 911 390 (1999-04-01), None
patent: 0 911 398 (1999-04-01), None
patent: 0 618 968 (1999-10-01), None
patent: 1067386 (2001-01-01), None
patent: WO 89/03993 (1989-05-01), None
patent: WO 93/03148 (1993-02-01), None
patent: WO 93/03177 (1993-02-01), None
patent: WO 93/03369 (1993-02-01), None
patent: WO 93/11231 (1993-06-01), None
patent: WO 95/05466 (1995-02-01), None
patent: WO 96/04915 (1996-02-01), None
patent: WO 96/05837 (1996-02-01), None
patent: WO 96/30766 (1996-10-01), None
patent: WO 99/62548 (1999-12-01), None
patent: WO 01/53340 (2001-07-01), None
patent: WO 02/055720 (2002-07-01), None
patent: WO 02/059150 (2002-08-01), None
patent: WO 02/075318 (2002-09-01), None
patent: WO 03/007933 (2003-01-01), None
patent: WO 2005/030676 (2005-04-01), None
patent: WO 2006/032879 (2006-03-01), None
patent: WO 2007/110627 (2007-10-01), None
patent: WO 2007/110629 (2007-10-01), None
Allen, et al., “Abnormal Bleeding—II; Further Clinical Experience With Toluidine Blue and Protamine Sulfate,” pp. 692-703.
Anderton, et al., “Dendritic Changes in Alzheimer's Disease and Factors that May Underlie These Changes,” P. Neurobiology, pp. 595-609, vol. 33.
Bancher, et al., “Accumulation of Abnormally Phosphorylated τ Precedes the Formation of Neurofibrillary Tangles in Alzheimer's Disease,” Brain Research, 1989, pp. 90-99, vol. 477.
Biernat, et al., “The Switch of Tau Protein to an Alzheimer-like State Includes the Phosphorylation of Two Serine—Proline Motifs Upstream of the Microtubule Binding Region,” 1992, pp. 1593-1597.
Brandt, R., “Cytoskeletal Mechanisms of Axon Outgrowth and Pathfinding,” Cell Tissue Res., 1998, pp. 181-189, vol. 292.
Brion, et al., Characterization of a Partial cDNA Specific for the High Molecular Weight Microtubule-Associated Protein MAP2 That Encodes Epitopes Shared with Paired Helical Filaments of Alzheimer's Disease, Dementia, 1990, pp. 304-315, vol. 1.
Callaway, et al., “Methylene Blue Restores Spatial Memory Retention Impaired by an Inhibitor of Cytochrome Oxidase in Rats,” Neuroscience Letters, 2002, pp. 83-86, vol. 332.
Caputo, et al., “Amyloid-Like Properties of a Synthetic Peptide Corresponding to the Carboxy Terminus of β-Amyloid Protein Precursor,” Archives of Biochemistry and Biophysics, Jan. 1992, pp. 199-205, vol. 292, No. 1.
Caputo, et al., “The Amyloid Proteins of Alzheimer's Disease as Potential Targets for Drug Therapy,” Neurobiology of Aging, 1989, pp. 451-461, vol. 10.
Condamines, et al., “New Immunoassay for the Mapping of Neurofibrillary Degeneration in Alzheimer's Disease Using Two Monoclonal Antibodies Against Human Paired Helical Filament Tau Proteins,” Neuroscience Letters, 1995, pp. 81-84, vol. 192.
Cudd, et al., “Pharmacokinetics and Toxicity of Tolonium Chloride in Sheep,” Original Research, Vet. Human Toxicol., Oct. 1996, pp. 329-332, vol. 38, No. 5.
De Garcini, Esteban Montejo et al., “In Vitro Conditions for the Self-Polymerization of the Microtubule-Associated Protein, Tau Factor”, J. Biochem, (1987) pp. 1415-1421, vol. 102.
De Garcini, Esteban Montejo et al., “Self Assembly of Microtubule Associated Protein Tau Into Filament Resembling Those Found in Alzheimer Disease”, Giochemical and Biophysical Research Communications, (1985) pp. 790-796, vol. 141, No. 2.
De Garcini, Esteban Montejo et al., “Tau factor polymers are similar to paired helical filaments of Alzheimer's disease”, FEBS, (1988) pp. 150-154, vol. 236, No. 1.
DeTure, et al., “In Vitro Assembly of Alzheimer-like Filaments: How a Small Cluster of Charged Residues in Tau and MAP2 Controls Filament Morphology,” JBC Papers in Press, May 2002, Manuscript M201201200, p. 1-21 (plus figures).
Epstein, et al., “The Utility of Toluidine Blue Application as a Diagnostic Aid in Patients Previously Treated for Upper Oropharyngeal Carcinoma,” Oral Surgery Oral Medicine Oral Pathology, May 1997, pp. 537-547, vol. 83, No. 5.
Fasulo, et al., “Overexpression of Alzheimer's PHF Core Tau Fragments: Implications for the Tau Truncation Hypothesis,” Alzheimer's Research, 1996, pp. 195-200, vol. 2, No. 5.
Friedhoff, et al., “A Nucleated Assembly Mechanism of Alzheimer Paired Helical Filaments,” Proc. Natl. Acad. Sci., Dec. 1998, pp. 15712-15717, vol. 95, USA.
Friedhoff, et al., “Rapid Assembly of Alzheimer-like Paired Helical Filaments from Microtubule-Associated Protein Tau Monitored by Fluorescence in Solution,” Biochemistry, 1998, pp. 10223-10230, vol. 37, No. 28.
Garcie de Ancos, et al., “Differences in Microtubule Binding and Self-association Abilities of Bovine Brain Tau Isoforms,” J. Biol. Chem., Apr. 1993, pp. 7976-7982, vol. 268, No. 11.
Giannetti, et al., “Fibers of Tau Fragments, But Not Full Length Tau, Exhibit a Cross βStructure: Implications for the Formation of Paired Helical Filaments,” Protein Science, 2000, pp. 2427-2435, vol. 9, Cambridge University Press, USA.
Goedert, et al., “Cloning and Sequencing of the cDNA Encoding a Core Protein of the Paired Helical Filament of Alzheimer Disease: Identification as the Microtubule-associated Protein Tau,” Proc. Natl. Acad. Sci., Jun. 1988, pp. 4051-4055, vol. 85, USA.
Goedert, et al., “Tau Proteins of Alzheimer Paired Helical Filaments: Abnormal Phosphorylation of All Six Brain Isoforms,” Neuron, Jan. 1992, pp. 159-168, vol. 8, Cell Press.
Götz, et al., “Tau Filament Formation in Transgenic Mice Expressing P301L Tau,” JBC Papers in Press, 2000 (Manuscript M006531200), pp. 1-24 (plus figures) [online, retrieved on Jan. 17, 2006]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list>.
Grover, et al., “5' Splice Site Mutations intauAssociated with the Inherited Dementia FTDP-17 Affect a Stem-Loop Structure That Regulates Alternative Splicing of Exon 10,” J. Biol. Chem., May 1999, pp. 15134-15143, Vol. 274, No. 21.
Grundke-Iqbal, et al., “Abnormal Phosphorylation of the Microtubule-Associated Protein τ (tau) in Alzheimer Cytoskelet
Harrington Charles R.
Horsley David
Marshall Colin
Rickard Janet E.
Sinclair James P.
Blanchard David J
Foley & Lardner LLP
Klinkel Kortney L
Wista Laboratories Ltd.
LandOfFree
Methods of treatment of a tauopathy condition comprising the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment of a tauopathy condition comprising the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment of a tauopathy condition comprising the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228198